BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 30, 2012) Lester Kobzik M.D., BioAegis Scientific Advisor and collaborator from Harvard School of Public Health, has made important medical discoveries about plasma gelsolin’s role in boosting immune function to target a broad range of pathogens. Dr. Kobzik is pursuing work in secondary pneumonia under a $1 million NIH grant to support advancement of our plasma gelsolin work.

Company Requested to Submit White Papers Following IND

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 15, 2012) BioAegis Therapeutics Inc. announced that it has presented its plasma gelsolin technology platform to scientists at the Biological Advanced Research Development Agency (BARDA). Data shared at the meeting demonstrated the ability of plasma to address biological threats, including radiation exposure and potential pandemics. TechWatch meetings enable industry participants to brief the agency on new and innovative technology. The meetings are applied for and granted if the technology is of high interest.

BioAegis’ Patent Rights Extend to Applications for Inflammation

Recombinant plasma gelsolin has been shown to be a biomarker of inflammation in a wide range of diseases and in particular in rheumatoid arthritis (RA). This abundant human plasma protein is expected to have utility in patients with RA, as well as other inflammatory diseases.

Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and Women’s Hospital, and American Cancer Society Professor of Medicine, Harvard Medical School and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center and BloodCenter of Wisconsin. This exclusive option to a worldwide license encompasses therapeutic and diagnostic uses of the technology for human and animal applications.